Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glycopyrronium bromide pMDI in COPD – randomized double-blind placebo-controlled 2-way crossover study
2013-005268-25Phase 2Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of glycopyrronium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Change from baseline in pre-dose morning FEV1 on Day 28. Started Mar 2014; status: completed.
02
Drugs
glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2013-005268-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005268-25.